Abagovomab

• CAT Number: I042431
• CAS Number: 792921-10-9
• Purity: ≥95%

Abagovomab (Cat No.: I042431) is a murine monoclonal antibody developed as a therapeutic vaccine targeting cancer antigen CA125, commonly overexpressed in ovarian cancer. It acts as an anti-idiotypic antibody, mimicking CA125 to stimulate the immune system to generate a targeted anti-tumor response. Designed to help prevent cancer recurrence following chemotherapy, abagovomab aimed to enhance long-term immune surveillance. Despite promising early-phase results, it failed to show significant clinical benefit in phase III trials. Nevertheless, it remains a notable example in cancer immunotherapy research.

Reference

[1]. Pfisterer J, et al. The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR. Ann Oncol. 2006 Oct;17(10):1568-77.
[Content Brief]

[2]. Grisham RN, et al. Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer. Immunotherapy. 2011 Feb;3(2):153-62.
[Content Brief]